THANK YOU FOR SUBSCRIBING
Ajax Health ("Ajax"), a privately held clinical-stage platform organization concentrated on creating medical advances, declared today the end of an oversubscribed $120 million Series B round of funding with support from a solid syndicate of new and existing investors. New financial supporters include ICONIQ Capital, HealthQuest Capital, Polaris Partners, WTI, and select other individual and vast family office investors. Majority investors KKR and existing supporters Aisling Capital additionally took an interest in the financing.
Ajax was established in 2017 by Duke Rohlen, a successful pharma business person and official, in association with KKR and Aisling Capital. Ajax's technique is concentrated on de-risked medical innovation opportunities. Ajax distinguishes areas of under-served medicinal need and matches human and financial capital to propel innovations and develop technique.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“We are thrilled to welcome into Ajax this exceptional, new investor syndicate. Their confidence in Ajax underscores the opportunity that Ajax sees to accelerate investment and innovation in an undervalued medical technology sector. There is a significant need in the medical device space for capital to be deployed into differentiated technologies that leverage seasoned operational teams and rational business models. The new group of investors in Ajax recognizes this opportunity and, with this investment, catalyzes the opportunity for important therapeutic innovation,” said Mr. Rohlen. Founder of Ajax Health
The company clusters its investments around therapeutic verticals, such as electrophysiology, and capitalizes on funding inefficiencies that stem from the scarcity of capital in the medical technology space.
Check Out This:
More in News